Nuvectis Pharma, Inc.
NVCT
$0.20
Change (1 day)
$12.10
Year High
$4.61
Year Low
Categories
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Revenue of Nuvectis Pharma, Inc. (NVCT)
Revenue in 2023 (TTM): $
According to Nuvectis Pharma, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Nuvectis Pharma, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-22,897,000 | $-22,897,000 | $-22,260,000 | $-22,260,000 |
| 2022 | $149 K | $-19,085,000 | $-19,234,000 | $-19,085,000 | $-18,787,000 |
| 2021 | $ | $-12,894,000 | $-12,894,000 | $-12,890,000 | $-12,886,000 |
| 2020 | $ | $ | $ | $-10,000 | $-10,000 |